Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$23.83 USD
-1.26 (-5.02%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $23.83 0.00 (0.00%) 7:22 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RNA 23.83 -1.26(-5.02%)
Will RNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Other News for RNA
Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by Xtalks
Artisan International Small-Mid Fund Q1 2024 Earnings Preview
Interesting RNA Put And Call Options For December 20th
Edgewise gets EU orphan drug status for muscular dystrophy drug
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)